Shares of Immumetp Ltd. IMMP,
, an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer. The company said overall survival data from a Phase 2b study evaluating its lead product candidate eftilagimod alpha in combination with chemotherapy performed well compared with placebo and chemotherapy. The overall trend in OS in total population was a median survival benefit of plus 2.7 months. However, in patients under 65 years of age, the benefit was 7.1 months. The data were presented at the San Antonio Breast Cancer Symposium which is taking place this week. Although the progression free survival data in the efti group did not show a significant improvement versus the comparator arm in AIPAC earlier this year, the OS data in general looks already very interesting and will mature further, AIPAC Principal Investigator, Hans Wildiers of University Hospital Leu
UPDATE: Immutep shares soar 190% on positive results in trial of breast cancer treatment msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Socio-Economic Factors, Policy Changes Impact Disparities Among Breast Cancer Patients pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
UPDATE: Immutep shares soar 190% on positive results in trial of breast cancer treatment MarketWatch 12/10/2020
MARKET PULSE
Shares of Immumetp Ltd. an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer. The company said overall survival data from a Phase 2b study evaluating its lead product candidate eftilagimod alpha in combination with chemotherapy performed well compared with placebo and chemotherapy. The overall trend in OS in total population was a median survival benefit of plus 2.7 months. However, in patients under 65 years of age, the benefit was 7.1 months. The data were presented at the San Antonio Breast Cancer Symposium which is taking place this week. Although the progression free survival data in the efti group did not show a significant improvement versus the comparator arm in AIPAC earlier this year, the OS data in general looks already very in